104 related articles for article (PubMed ID: 19417156)
1. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.
Maksimovic-Ivanic D; Mijatovic S; Miljkovic D; Harhaji-Trajkovic L; Timotijevic G; Mojic M; Dabideen D; Cheng KF; McCubrey JA; Mangano K; Al-Abed Y; Libra M; Garotta G; Stosic-Grujicic S; Nicoletti F
Mol Cancer Ther; 2009 May; 8(5):1169-78. PubMed ID: 19417156
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells.
Mijatovic S; Maksimovic-Ivanic D; Mojic M; Timotijevic G; Miljkovic D; Mangano K; Donia M; Di Cataldo A; Al-Abed Y; Cheng KF; Stosic-Grujicic S; Nicoletti F
J Cell Physiol; 2011 Jul; 226(7):1803-12. PubMed ID: 21506111
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.
Donia M; Maksimovic-Ivanic D; Mijatovic S; Mojic M; Miljkovic D; Timotijevic G; Fagone P; Caponnetto S; Al-Abed Y; McCubrey J; Stosic-Grujicic S; Nicoletti F
Cell Cycle; 2011 Feb; 10(3):492-9. PubMed ID: 21270522
[TBL] [Abstract][Full Text] [Related]
4. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
Rothweiler F; Michaelis M; Brauer P; Otte J; Weber K; Fehse B; Doerr HW; Wiese M; Kreuter J; Al-Abed Y; Nicoletti F; Cinatl J
Neoplasia; 2010 Dec; 12(12):1023-30. PubMed ID: 21170266
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.
Mojic M; Mijatovic S; Maksimovic-Ivanic D; Miljkovic D; Stosic-Grujicic S; Stankovic M; Mangano K; Travali S; Donia M; Fagone P; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
Mol Pharmacol; 2012 Oct; 82(4):700-10. PubMed ID: 22798453
[TBL] [Abstract][Full Text] [Related]
6. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.
Mojic M; Mijatovic S; Maksimovic-Ivanic D; Dinic S; Grdovic N; Miljkovic D; Stosic-Grujicic S; Tumino S; Fagone P; Mangano K; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
Cell Cycle; 2012 Mar; 11(6):1174-82. PubMed ID: 22370480
[TBL] [Abstract][Full Text] [Related]
7. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells.
Donia M; Mangano K; Fagone P; De Pasquale R; Dinotta F; Coco M; Padron J; Al-Abed Y; Giovanni Lombardo GA; Maksimovic-Ivanic D; Mijatovic S; Zocca MB; Perciavalle V; Stosic-Grujicic S; Nicoletti F
Oncol Rep; 2012 Aug; 28(2):682-8. PubMed ID: 22665020
[TBL] [Abstract][Full Text] [Related]
8. The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.
Maksimovic-Ivanic D; Mojic M; Bulatovic M; Radojkovic M; Kuzmanovic M; Ristic S; Stosic-Grujicic S; Miljkovic D; Cavalli E; Libra M; Fagone P; McCubrey J; Nicoletti F; Mijatovic S
Leuk Res; 2015 Oct; 39(10):1088-95. PubMed ID: 26220866
[TBL] [Abstract][Full Text] [Related]
9. Saquinavir-NO inhibits IL-6 production in macrophages.
Momčilović M; Mangano K; Jevtić B; Mammana S; Stošić-Grujičić S; Nicoletti F; Miljković D
Basic Clin Pharmacol Toxicol; 2014 Dec; 115(6):499-506. PubMed ID: 24842127
[TBL] [Abstract][Full Text] [Related]
10. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.
Canducci F; Ceresola ER; Saita D; Al-Abed Y; Garotta G; Clementi M; Nicoletti F
Antiviral Res; 2011 Sep; 91(3):292-5. PubMed ID: 21763726
[TBL] [Abstract][Full Text] [Related]
11. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
12. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.
Alami N; Page V; Yu Q; Jerome L; Paterson J; Shiry L; Leyland-Jones B
Growth Horm IGF Res; 2008 Dec; 18(6):487-96. PubMed ID: 18502161
[TBL] [Abstract][Full Text] [Related]
14. Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway.
O'Kelly J; Uskokovic M; Lemp N; Vadgama J; Koeffler HP
J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):107-16. PubMed ID: 16777406
[TBL] [Abstract][Full Text] [Related]
15. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Gills JJ; Lopiccolo J; Tsurutani J; Shoemaker RH; Best CJ; Abu-Asab MS; Borojerdi J; Warfel NA; Gardner ER; Danish M; Hollander MC; Kawabata S; Tsokos M; Figg WD; Steeg PS; Dennis PA
Clin Cancer Res; 2007 Sep; 13(17):5183-94. PubMed ID: 17785575
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway.
Chen J; Wang T; Xu S; Zhang P; Lin A; Wu L; Yao H; Xie W; Zhu Z; Xu J
Eur J Med Chem; 2017 Jul; 135():414-423. PubMed ID: 28463784
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo.
Paskas S; Mazzon E; Basile MS; Cavalli E; Al-Abed Y; He M; Rakocevic S; Nicoletti F; Mijatovic S; Maksimovic-Ivanic D
Invest New Drugs; 2019 Oct; 37(5):1014-1028. PubMed ID: 30706336
[TBL] [Abstract][Full Text] [Related]
18. Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells.
Pereira M; Vale N
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293096
[TBL] [Abstract][Full Text] [Related]
19. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo.
Maksimovic-Ivanic D; Mijatovic S; Harhaji L; Miljkovic D; Dabideen D; Fan Cheng K; Mangano K; Malaponte G; Al-Abed Y; Libra M; Garotta G; Nicoletti F; Stosic-Grujicic S
Mol Cancer Ther; 2008 Mar; 7(3):510-20. PubMed ID: 18347138
[TBL] [Abstract][Full Text] [Related]
20. A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo.
Mäemets-Allas K; Viil J; Jaks V
Mol Cancer Ther; 2015 Nov; 14(11):2486-96. PubMed ID: 26294745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
